Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Margins recover swiftly to historical 8% highs, and Optum drives accelerated growth, unlocking the high-end valuation.
Permanent MA Rate Cuts: Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.
Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.
Reduce rating assigned.
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs; Dual SNPs; Long-Term Services and Supports; Aged, Blind and Disabled; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.
A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROIC below WACC and stalling free cash flow generation indefinitely.
Massive scale, vertical integration across payers and providers (Optum + UHC), and immense data network effects.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $17.1B after capex $3.6B, with terminal value at 69.0% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If MCR misses high, the stock rerates lower due to margin fears. If Optum margins expand materially, it offsets UHC pressure and stabilizes EPS.
If MCR misses high, the stock rerates lower due to margin fears. If Optum margins expand materially, it offsets UHC pressure and stabilizes EPS.
If MCR misses high, the stock rerates lower due to margin fears. If Optum margins expand materially, it offsets UHC pressure and stabilizes EPS.
If MCR misses high, the stock rerates lower due to margin fears. If Optum margins expand materially, it offsets UHC pressure and stabilizes EPS.
Highly cash-generative; capital deployment aggressively favors massive share repurchases and strategic vertical M&A.
Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.
Elevated post-pandemic medical utilization, aggressive CMS rate cuts, and intense political scrutiny.
Highly cash-generative; capital deployment aggressively favors massive share repurchases and strategic vertical M&A.
Given the Reduce rating and -10.07% downside to fair value, allocate underweight or zero new capital.
Take profits or trim exposure at current levels above $378, given structurally capped upside and margin realities.
We rate UNH a Reduce (or Hold for strictly long-term, tax-sensitive accounts). The heavily penalized $339.99 midpoint reflects near-term operational realities.
While UNH remains a phenomenal business with unmatched scale, the current market valuation fails to fully price in acute margin shocks and persistent regulatory headwinds.
We rate UNH a Reduce (or Hold for strictly long-term, tax-sensitive accounts). The heavily penalized $339.99 midpoint reflects near-term operational realities.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Persistent MCR pressure and regulatory headwinds cause structural operating margin compression, dragging fair value to the downside.
Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.
Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.
Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.
The five developments that would weaken our investment case.
Severe medical cost inflation and elevated healthcare utilization would compress core underwriting profitability, eroding underwriting spreads and constraining capital reinvestment into value-based care initiatives across integrated clinical networks.
Current:18.5% for the period ended 2025-12-31
Alert ifDeclines below 17.0% over any trailing twelve-month period
Sharp deceleration in top-line growth indicates commercial membership losses and reduced care delivery volume, undermining the enterprise expansion flywheel and diminishing long-term compounding across healthcare services.
Current:11.8% for the period ended 2025-12-31
Alert ifDecelerates below 5.0% over any fiscal year
Persistent inability to expand operating margins indicates structural medical loss headwinds and unrecovered administrative expenses, reducing operating leverage and suppressing consolidated earnings generation.
Current:4.2% for the period ended 2025-12-31
Alert ifRemains below 5.0% across two consecutive fiscal years
Permanent regulatory payment rate cuts and restrictive margin caps would diminish segment return spreads over capital costs, impairing overall corporate capital productivity and destroying economic value creation.
Current:8.6% as of the 2026-05-08 analysis date
Alert ifDrops below 7.0% over any trailing twelve-month period
Inadequate conversion of accounting net income into realized operating cash flow signals working capital absorption or aggressive reserve timing, directly constraining share repurchases, debt reduction, and strategic acquisitions.
Current:1.634 as of the 2026-05-08 analysis date
Alert ifFalls below 1.00x over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Margins recover swiftly to historical 8% highs, and Optum drives accelerated growth, unlocking the high-end valuation.
Near-term stagnation is followed by a gradual margin recovery to 6%, with a terminal multiple of 18x safely anchoring valuation.
Warning level: Declines below 17.0% over any trailing twelve-month period. Severe medical cost inflation and elevated healthcare utilization would compress core underwriting profitability, eroding underwriting spreads and constraining capital reinvestment into value-based care initiatives across integrated clinical networks.
Warning level: Decelerates below 5.0% over any fiscal year. Sharp deceleration in top-line growth indicates commercial membership losses and reduced care delivery volume, undermining the enterprise expansion flywheel and diminishing long-term compounding across healthcare services.
Warning level: Remains below 5.0% across two consecutive fiscal years. Persistent inability to expand operating margins indicates structural medical loss headwinds and unrecovered administrative expenses, reducing operating leverage and suppressing consolidated earnings generation.
Warning level: Drops below 7.0% over any trailing twelve-month period. Permanent regulatory payment rate cuts and restrictive margin caps would diminish segment return spreads over capital costs, impairing overall corporate capital productivity and destroying economic value creation.
Warning level: Falls below 1.00x over any trailing twelve-month period. Inadequate conversion of accounting net income into realized operating cash flow signals working capital absorption or aggressive reserve timing, directly constraining share repurchases, debt reduction, and strategic acquisitions.
| $287.60B |
| $324.16B |
| $371.62B |
| $400.28B |
| $447.57B |
| +11.7% |
| Gross profit | $69.65B | $79.62B | $90.96B | $89.40B | $82.92B | +4.5% |
| Operating income | $23.97B | $28.44B | $32.36B | $23.98B | $18.70B | -6.0% |
| Net income | $17.29B | $20.12B | $22.38B | $14.41B | $12.06B | -8.6% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | -7.5% |
| EBITDA | $27.07B | $31.84B | $36.33B | $28.08B | $23.06B | -3.9% |
| R&D | — | — | — | — | — | — |
| SG&A | — | — | — | — | — | — |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 447,567,000,000 |
|---|---|
| Cost of revenue | 364,650,000,000 |
| Gross profit | 82,917,000,000 |
| Operating expenses | 63,953,000,000 |
| Operating income | 18,964,000,000 |
| Non-operating items and tax | -6,908,000,000 |
| Net income | 12,056,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 287.6B | 27.1B | 17.3B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.3% | — | — | — |
| 2022-12-31 | 324.2B | 31.8B | 20.1B | 26.2B | 23.4B | 2.8B | 3.4B | 925M | 7B | 6B | 12.5B | — | — | — | — | 23.4B | 57.6B | 8.8% | — | 6.9% | — |
| 2023-12-31 | 371.6B | 36.3B | 22.4B | 29.1B | 25.7B | 3.4B | 4B | 1.1B | 8B | 6.8B | 4.3B | — | — | — | — | 25.4B | 62.5B | 8.7% | — | 6.5% | — |
| 2024-12-31 | 400.3B | 28.1B | 14.4B | 24.2B | 20.7B | 3.5B | 4.1B | 1B | 9B | 7.5B | 14.7B | — | — | — | — | 25.3B | 76.9B | 8.1% | — | 7.0% | — |
| 2025-12-31 | 447.6B | 23.1B | 12.1B | 19.7B | 16.1B | 3.6B | 4.4B | 971M | 5.5B | 7.9B | 726M | — | — | — | — | 24.4B | 78.4B | 4.2% | — | 5.0% | — |
UNH trades at 18.2x forward earnings against a peer median of 12.3x; EV/EBITDA of 18.2x against a peer median of 7.4x; 6 peers.
| Elevance Health Inc. |
| 12.8x |
| 0.4x |
| 8.9x |
| 12.1% |
| 5.3% |
| CI | The Cigna Group | 8.5x | 0.3x | 7.4x | 16.3% | 5.5% |
| HUM | Humana Inc. | 16.2x | 0.2x | 6.6x | 6.3% | 4.7% |
| CNC | Centene Corporation | 12.3x | 0.2x | 6.9x | -26.0% | 5.1% |
